High cholesterol levels change the association of biomarkers of neurodegenerative diseases with dementia risk: Findings from a population-based cohort

Laura Perna1,2  |  Ute Mons3,4  |  Hannah Stocker4,5  |  Léon Beyer6,7  |  Konrad Beyreuther5  |  Kira Trares4,5,8  |  Bernd Holleczek9  |  Ben Schöttker4,5  |  Robert Perneczky2,10,11,12,13  |  Klaus Gerwert6,7  |  Hermann Brenner4,5

1Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
2Division of Mental Health of Older Adults, Department of Psychiatry and Psychotherapy, University Hospital LMU, Munich, Germany
3Department of Cardiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
4Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
5Network Aging Research (NAR), Heidelberg University, Heidelberg, Germany
6Faculty of Biology and Biotechnology, Department of Biophysics, Ruhr-University Bochum, Bochum, Germany
7Center for Protein Diagnostics (ProDi), Ruhr-University Bochum, Bochum, Germany
8Medical Faculty, Heidelberg University, Heidelberg, Germany
9Saarland Cancer Registry, Saarbrücken, Germany
10Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, UK
11German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
12Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
13Sheffield Institute for Translational Neurology (SITran), University of Sheffield, Sheffield, UK

Abstract

Introduction: This study assessed whether in a population with comorbidity of neurodegenerative and cerebrovascular disease (mixed pathology) the association of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau181 (p-tau181) with dementia risk varied depending on levels of total cholesterol and apolipoprotein E (APOE) ε4 genotype.

Methods: Plasma biomarkers were measured using Simoa technology in 768 participants of a nested case-control study embedded within an ongoing population-based cohort. Logistic and spline regression models, and receiver operating characteristic curves were calculated.

Results: The strength of the association between GFAP and NfL with risk of a clinical diagnosis of dementia changed depending on cholesterol levels and on APOE ε4 genotype. No significant association was seen with p-tau181.
1 | BACKGROUND

Dementia is a progressive syndrome characterized by deterioration of cognitive, functional, and behavioral abilities. It has long been established that physical and mental health are fundamentally linked and that a healthy body is an essential precondition of a healthy brain and vice versa. One of the main mechanisms linking body and brain health is the maintenance of a good vascular health and there is strong evidence indicating that several modifiable risk factors for dementia are also risk factors for vascular pathology and that better cardiovascular health leads to better cognitive health.

Raised plasma cholesterol, especially low-density lipoprotein cholesterol (LDL), is one of the major risk factors for ischemic heart disease and ischemic stroke and, according to worldwide estimates, it has a prevalence of approximately 39% among adults. High cholesterol is also considered to be a potentially modifiable risk factor for dementia risk, but the mechanisms linking high cholesterol to dementia are not clear and the findings relating to the association of cholesterol and dementia are mixed. In previous work, we found that the presence of high total cholesterol (TC), which is mostly composed of LDL, was associated with cognitive function only in the interplay with other risk factors, namely cardiovascular pathologies and apolipoprotein E (APOE) ε4 genotype. Here we investigate the role of hypercholesterolemia for dementia risk in connection not only with vascular pathology and APOE ε4, but also with established blood biomarkers of neurodegenerative diseases. As biomarkers, we selected glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau181 (p-tau181), because all these biomarkers have been consistently associated with dementia or dementia risk, and GFAP and NfL also with cerebrovascular disease, such as stroke.

Furthermore, altered levels of GFAP could point to a possible dysregulation of brain cholesterol synthesized by astrocytes, whose interconnections with peripheral cholesterol are yet unexplored.

Most dementia biomarker studies have been conducted in clinic-based research cohorts including very selected and well-characterized populations with evidence of amyloid beta (Aβ) plaques and tau tangles. We believe that to understand the impact of blood biomarkers on dementia fully, we also need to focus on representative populations with mixed pathologies (comorbidity of neurodegenerative and cerebrovascular disease, including, inter alia, vascular encephalopathy, cerebral infarction, microangiopathy), and investigate how such markers unfold in synergism with other risk factors. Hence, here we investigate whether in a population-based cohort with high prevalence of mixed pathology, hypercholesterolemia changes the association of blood biomarkers of neurodegenerative diseases with the risk of receiving a clinical diagnosis of dementia across 17 years of follow-up and whether this association is further moderated depending on APOE ε4 genotype. A secondary aim of the study was to investigate whether the additional presence of stroke prior to or at the time of the measurement of the biomarkers changed the magnitude of the association between biomarkers of neurodegenerative diseases and dementia risk.

2 | METHODS

2.1 | Study population

Data are based on a nested case-control study within a community-based prospective cohort of White older adults followed for up to 17 years regarding clinical diagnosis of various age-related diseases and mortality (the ESTHER study). ESTHER participants (n = 9940) were recruited between 2000 and 2002 in Saarland, a southwestern German state. Eligibility criteria were age between 50 and 75 years, sufficient knowledge of the German language, residence in Saarland, and willingness to attend a general health examination performed by general practitioners (GPs). No specific exclusion criteria were applied, as this would have impaired the generalizability of the ESTHER study. Both at baseline and at follow-up participants provided health information and biological samples, including blood samples, which
were stored at -80°C. The ESTHER study was approved by the Ethics Committee of the Medical Faculty at Heidelberg University and the Physicians’ Board of Saarland. All participants provided written informed consent.

2.2 | Dementia assessment

During the 14- and 17-year follow-up, the GPs of 8353 ESTHER study participants (84%) could still be contacted and were asked to provide information relating to a diagnosis of dementia since enrollment and to send the corresponding medical records, if available.25 GPs of participants who had dropped out of the study or had died were also contacted. From the available medical records it could be inferred that most dementia cases, independently of the dementia form reported by the GPs, also had cerebrovascular pathologies including encephalopathy, cerebral infarction, and microangiopathy. Both dementia diagnoses and cerebrovascular pathologies were mostly listed in the medical reports as an acquired diagnosis, but only limited details on the corresponding diagnostic procedures were provided. While the performance of a computed tomography or a magnetic resonance imaging was often reported, dementia diagnoses were rarely supported by biomarkers. All diagnostic procedures had to follow, as a minimum requirement, the International Classification of Diseases (ICD-10), because this is the official classification for the encoding of medical diagnoses in Germany.

In light of results of clinical–pathological studies performed among population-based cohorts showing that vascular pathologies are the most prevalent pathologies among demented patients,26–27 and based on the observation that pure Alzheimer’s disease (AD) pathology is very rare,28 we hence assume that in the ESTHER cohort even in cases where AD dementia or vascular dementia is reported as primary diagnosis, mixed pathologies were likely to be present in the great majority of dementia cases. Hence, we will use the term dementia risk to indicate the risk of a clinical diagnosis of dementia reflecting a composite endpoint including a diagnosis of the clinical syndrome of AD (AD dementia), vascular dementia, and mixed dementia, with AD and vascular dementia indicating predominance of clinical symptoms closer to neurodegenerative or cerebrovascular pathologies, respectively. The present dataset included 507 controls (participants that remained without dementia diagnosis throughout follow-up) chosen at random and 261 dementia cases (dementia diagnosis occurring between baseline and the 17-year follow-up), as previously described.25

2.3 | Laboratory measurements

2.3.1 | Blood biomarkers for neurodegenerative diseases

GFAP, NfL, and p-tau181 were measured in a single batch in lithium-heparin plasma of baseline samples at the Center for Protein Diagnostics (PRODI) of Bochum University (Germany) using the single molecule array (Simoa) Neurology 4-Plex E Advantage Kit and Simoa pTau-181 Advantage V2 Kit (Quanterix) on a HD-X Analyzer as per manufacturer’s instructions. Upon arrival at the laboratory the samples were thawed at room temperature and mixed thoroughly. After a centrifugation step at 10,000 × g for 5 minutes they were applied to a conical 96-well plate (Quanterix) and measured immediately, along with lot-specific calibrators and one low and one high concentrated lot-specific controls.25 Measurements of Aβ40 and Aβ42 were also performed, but the levels were below the limit of detection, possibly due to the use of lithium-heparin plasma instead of ethylenediaminetetraacetic acid plasma as recommended by the manufacturer. Hence measurements of Aβ could not be used and were excluded from the analyses.

2.3.2 | Total cholesterol

Cholesterol levels were determined in all ESTHER participants at baseline, with samples taken at the same time as the plasma used to measure the blood biomarkers. Cholesterol concentrations were measured in serum using a timed-endpoint method by which cholesterol esterase hydrolyzes esters to free cholesterol (Beckman Coulter SYNCHRON System[s]). The measurements were performed in the Laboratory of the University Clinic Heidelberg, Germany. Hypercholesterolemia was defined as TC ≥ 240 mg/dL.30–31
2.3.3  APOE ε4 genotyping

ε4 alleles were determined based on allelic combinations of single nucleotide polymorphisms (SNP) rs7412 and rs429358 using TaqMan SNP genotyping assays. Genotypes were analyzed in an endpoint allelic discrimination read using a PRISM 7000 Sequence detection system (Applied Biosystems). In some cases with missing values (n = 38) the APOE genotype could be determined based on APOE SNP results from genome-wide association study data. Participants were divided into carriers of the ε4 allele (ε2/ε4, ε3/ε4, ε4/ε4) and non-carriers (ε2/ε2, ε2/ε3, ε3/ε3).

2.4 Stroke and sociodemographic data

Medical diagnoses of stroke were made either at or prior to baseline and were self-reported. Detailed information on diagnostic procedures was not available. Age, sex, and educational level (less/equal to, or higher than 9 years of school education) were collected through the self-administered questionnaire administered at baseline.

2.5 Statistical analysis

Main baseline characteristics of the included ESTHER cases and controls were described for the whole population and according to levels of TC. Multivariable logistic regression models adjusted for age, sex, educational level, TC, and APOE ε4 genotype were estimated for the outcome dementia. Biomarker values were divided into quartiles (Q), and odds ratios (OR) with 95% confidence intervals (CI) were calculated for the highest quartile (Q4) compared to the other three quartiles (Q1-3), serving as the reference group. All regression models were run for the overall sample, by levels of TC (high: ≥ 240 mg/dL; low < 240 mg/dL)[30-31] and by APOE ε4 genotype (carriers/non-carriers). Additional regression models adjusted for age and sex were performed stratified by stroke at baseline. The ORs in the main analyses were also calculated per one standard deviation (SD) increase of each biomarker. To assess whether outliers affected associations, the main results were repeated after excluding the outliers according to the interquartile range (IQR) method (Q3 + 1.5 x IQR). Interaction terms between biomarkers and cholesterol, APOE ε4, and stroke were also calculated and added to the regression models.

Dose-response analyses using restricted cubic spline functions (RCS) with knots at the 5th, 35th, 65th, and 95th percentiles were conducted. A receiver operating characteristic (ROC) curve was calculated to explore the discriminative power of the blood biomarkers in addition to age, sex, educational level, and APOE ε4 (main model). RCS functions and ROC curves were derived separately in subgroups with high and low TC; the values of GFAP, NfL, and p-tau181 were inserted as continuous variables. For all three biomarkers, the distributions were moderately right skewed. However, because the data were reasonably close to a normal distribution and for better interpretability, we used the original values. All analyses were performed with the statistical software SAS, version 9.4.

3 RESULTS

3.1 General characteristics of the study population

In this nested case-control study, most cases and controls were older than 60 years and a large majority had a low educational level (Table 1). In total, n = 94 (36%) cases and n = 194 (38%) controls had high TC and both among cases and controls this percentage was higher among APOE ε4 carriers than among non-carriers (cases: 42% vs. 32%, controls: 41% vs. 38%). For all three biomarkers, levels were higher among cases. Mean follow-up time from recruitment in the study until clinical diagnosis of dementia was 9.9 years.

3.2 Markers of neurodegenerative diseases and total cholesterol

In the whole study population the values separating Q3 from Q4 were 123.50 pg/ml for GFAP, 21.50 pg/ml for NfL, and 2.07 pg/ml for p-tau181. Results of regression analyses showed that the odds of a dementia diagnosis were higher among participants with both high baseline levels of blood biomarkers and high TC levels than among participants with low TC (Table 2). This pattern was particularly evident for GFAP and NfL, for which ORs among participants with high TC were 5.10 (CI 2.45–10.60) and 2.96 (CI 1.43–6.14), respectively. For comparison, the ORs among participants with low TC were 2.44 (CI 1.47–4.07) and 1.15 (CI 0.69–1.92), respectively. After excluding the outliers (GFAP: ≥ 214.7 pg/ml, NfL ≥ 36.5 pg/ml, p-tau181 ≥ 3.5 pg/ml the values for Q4 in this restricted population were ≥ 118.0 pg/ml for GFAP, ≥ 20.5 pg/ml for NfL, and ≥ 1.9 pg/ml for p-tau181. The odds for dementia were 2.63 (95% CI 1.74–3.99) for GFAP, 1.49 (95% CI 0.98–2.27) for NfL, and 1.32 (95% CI 1.08–2.00) for p-tau181. The pattern of the odds relating to high and low TC remained stable (GFAP: 3.93, 95% CI 1.92–8.05; NfL: 2.89, 95% CI 1.36–6.16; p-tau181: 1.55, 95% CI 0.77–3.14 and GFAP = 2.16, 95% CI 1.29–3.61; NfL = 1.09, 95% CI 0.65–1.82; p-tau181: 1.21, 95% CI 0.71–2.04, respectively). In a regression model not including the biomarkers and adjusted for age, sex, educational level, and APOE ε4, hypercholesteremia was not independently associated with increased odds of dementia (OR = 0.95; 95% CI 0.66–1.37).

3.3 APOE ε4 genotype

The additional stratification of the models by APOE ε4 genotype revealed that the strongest association between GFAP and dementia risk was among non-carriers and between NL and dementia risk among carriers. These results were supported by interaction effects between GFAP x TC and NfL x TC, which were higher among APOE ε4– and APOE ε4+, respectively (Table S1 in supporting information). In a model adjusted for age and sex the interaction terms APOE ε4 x TC <240 mg/dL/<240 mg/dL and APOE ε4 x TC per SD for odds of dementia were 1.66 (95% CI 0.78–3.51) and 1.39 (95% CI 0.96–2.02),
### TABLE 1  Main baseline characteristics of the study population

<table>
<thead>
<tr>
<th></th>
<th>Dementia cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ESTHER study (n = 768)</td>
<td>Overall  n = 261</td>
</tr>
<tr>
<td></td>
<td>Overall n = 261</td>
<td>Overall n = 507</td>
</tr>
<tr>
<td></td>
<td>TC ≥ 240 mg/dL n = 94</td>
<td>TC ≥ 240 mg/dL n = 194*</td>
</tr>
<tr>
<td></td>
<td>TC &lt; 240 mg/dL n = 167</td>
<td>TC &lt; 240 mg/dL n = 312*</td>
</tr>
<tr>
<td>Age groups</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50–59</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>20 (7.7)</td>
<td>8 (8.5)</td>
<td>12 (7.2)</td>
</tr>
<tr>
<td>152 (58.2)</td>
<td>54 (57.5)</td>
<td>98 (58.7)</td>
</tr>
<tr>
<td>89 (34.1)</td>
<td>32 (34.0)</td>
<td>57 (34.1)</td>
</tr>
<tr>
<td>202 (39.8)</td>
<td>79 (40.7)</td>
<td>123 (39.4)</td>
</tr>
<tr>
<td>258 (50.9)</td>
<td>101 (52.1)</td>
<td>156 (50.0)</td>
</tr>
<tr>
<td>47 (9.3)</td>
<td>14 (7.2)</td>
<td>33 (10.6)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>151 (57.9)</td>
<td>278 (54.8)</td>
</tr>
<tr>
<td>Men</td>
<td>110 (42.1)</td>
<td>229 (45.2)</td>
</tr>
<tr>
<td>Educational level</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low a</td>
<td>214 (82.0)</td>
<td>394 (77.7)</td>
</tr>
<tr>
<td>High b</td>
<td>37 (14.2)</td>
<td>102 (20.1)</td>
</tr>
<tr>
<td>Missing values</td>
<td>10 (3.8)</td>
<td>11 (2.2)</td>
</tr>
<tr>
<td>APOE ε4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carriers c</td>
<td>103 (39.5)</td>
<td>131 (25.8)</td>
</tr>
<tr>
<td>Non-carriers d</td>
<td>143 (54.8)</td>
<td>364 (71.8)</td>
</tr>
<tr>
<td>Missing values</td>
<td>15 (5.8)</td>
<td>12 (2.4)</td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>18 (6.9)</td>
<td>9 (1.8)</td>
</tr>
<tr>
<td>No</td>
<td>229 (87.7)</td>
<td>481 (94.9)</td>
</tr>
<tr>
<td>Missing values</td>
<td>14 (5.4)</td>
<td>17 (3.4)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>GFAP</td>
<td>133.2 (78.2)</td>
<td>87.0 (46.7)</td>
</tr>
<tr>
<td>NfL</td>
<td>22.8 (13.4)</td>
<td>15.8 (8.4)</td>
</tr>
<tr>
<td>P-tau181</td>
<td>2.1 (1.5)</td>
<td>1.7 (1.2)</td>
</tr>
</tbody>
</table>

Abbreviations: APOE, apolipoprotein E; GFAP, glial fibrillary acidic protein; NfL, neurofilament light chain; p-tau181, tau phosphorylated at threonine 181; SD, standard deviation; TC, total cholesterol.

*The numbers sum up to 506 and not to 507 because one control measurement of cholesterol was not available.

a ≤ 9 years of school education.

b > 9 years of school education.

c Participants carrying APOE ε4 genotype (ε2/ε4, ε3/ε4, ε4/ε4).

d Participants not carrying APOE ε4 genotype (ε2/ε2, ε3/ε2, ε3/ε3).

respectively. Interaction terms between markers of neurodegeneration and APOE ε4 did not indicate any increase in the odds for dementia and the estimates did not reach a significance level < 0.05 for any biomarker (results not shown).

### 3.4 Diagnosis of stroke at baseline

Participants with lifetime history of stroke and high biomarker levels, especially NfL, had substantially increased odds of dementia (Table S2 in supporting information), a finding which was also reflected in increased odds for the interaction term between biomarkers and stroke in the whole cohort, but the small sample size of the study population and the very large CIs limit the interpretation of these results. Hence, for comparison, we also calculated the odds for dementia among participants with lifetime history of myocardial infarction (n = 44) and we observed that they were much lower than those seen for stroke (GFAP: 1.46 [95% CI 0.66–3.20], NfL: 1.09 [95% CI 0.61–1.93], p-tau181: 1.04 [95% CI 0.70–1.53]).

### 3.5 Dose-response association and ROC curves

Restricted cubic spline curves indicated a steadily increasing dose-response association between higher GFAP levels and dementia among...
participants with TC ≥ 240 mg/dL (Figure 1). For the other markers, dementia risk seemed to increase more strongly in participants with high TC levels, but leveled off with higher biomarker levels or even showed a tendency to decrease at higher NfL levels. ROC curve analyses for dementia showed that GFAP was the marker with the strongest discriminative ability in this cohort. However, the change in the area under the ROC curve (AUC) was small and the CIs were largely overlapping. Specifically, the AUC increased from 0.811 (95% CI 0.758–0.864) for the main model to 0.841 (95% CI 0.791–0.891) after the inclusion of GFAP in the group of participants with high TC and from 0.768 (95% CI 0.724–0.813) to 0.780 (95% CI 0.737–0.824) in the group with low TC (Figure 2). The inclusion of NfL and p-tau181 to the main model increased the AUC only marginally.

### Discussion

In this study, we examined associations of biomarkers of neurodegenerative diseases with dementia risk in a population with a high prevalence of mixed pathology and found that, especially for GFAP, the strength of the association changed depending on levels of TC and, partially, also on APOE ε4 genotype. Furthermore, the association of

---

**Table 2** Associations of GFAP, NfL, and p-tau181 with dementia risk by total cholesterol and APOE ε4 status (ESTHER cohort study 2000–2017)

<table>
<thead>
<tr>
<th>General population</th>
<th>Overall (Odds ratio*, 95% CI, n = cases)</th>
<th>TC ≥ 240 mg/dL (Odds ratio*, 95% CI, n = cases)</th>
<th>TC &lt; 240 mg/dL (Odds ratio*, 95% CI, n = cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glia fibrillary acidic protein</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GFAPQ4 (vs. Q1-3)</td>
<td>3.08 (2.04–4.66) (n = 261)</td>
<td>5.10 (2.45–10.60) (n = 94)</td>
<td>2.44 (1.47–4.07) (n = 167)</td>
</tr>
<tr>
<td>GFAP per 1 SD increase</td>
<td>1.66 (1.3-2.08)</td>
<td>2.54 (1.62–3.98)</td>
<td>1.41 (1.08–1.83)</td>
</tr>
<tr>
<td><strong>APOE ε4</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GFAPQ4 (vs. Q1-3)</td>
<td>3.13 (1.63–6.04) (n = 103)</td>
<td>2.40 (0.82–7.01) (n = 43)</td>
<td>3.90 (1.67–9.13) (n = 60)</td>
</tr>
<tr>
<td>GFAP per 1 SD increase</td>
<td>1.85 (1.30–2.62)</td>
<td>2.15 (1.21–3.83)</td>
<td>1.72 (1.10–2.68)</td>
</tr>
<tr>
<td><strong>Neurofilament light</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NfLQ4 (vs. Q1-3)</td>
<td>1.57 (1.04–2.38) (n = 261)</td>
<td>2.96 (1.43–6.14) (n = 94)</td>
<td>1.15 (0.69–1.92) (n = 167)</td>
</tr>
<tr>
<td>NfL per 1 SD increase</td>
<td>1.45 (1.15–1.82)</td>
<td>1.56 (1.09–2.24)</td>
<td>1.40 (1.03–1.89)</td>
</tr>
<tr>
<td><strong>APOE ε4</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NfLQ4 (vs. Q1-3)</td>
<td>1.30 (0.62–2.70) (n = 103)</td>
<td>4.21 (1.15–15.40) (n = 43)</td>
<td>0.67 (0.26–1.74) (n = 60)</td>
</tr>
<tr>
<td>NfL per 1 SD increase</td>
<td>1.24 (0.81–1.90)</td>
<td>2.04 (0.89–4.68)</td>
<td>1.04 (0.65–1.67)</td>
</tr>
<tr>
<td><strong>p-tau181</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-tau181Q4 (vs. Q1-3)</td>
<td>1.29 (0.86–1.93) (n = 261)</td>
<td>1.51 (0.77–2.98) (n = 94)</td>
<td>1.19 (0.72–1.97) (n = 167)</td>
</tr>
<tr>
<td>p-tau181 per 1 SD increase</td>
<td>1.18 (0.99–1.40)</td>
<td>1.23 (0.97–1.55)</td>
<td>1.13 (0.87–1.48)</td>
</tr>
<tr>
<td><strong>APOE ε4</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-tau181Q4 (vs. Q1-3)</td>
<td>0.99 (0.52–1.91) (n = 103)</td>
<td>1.10 (0.38–3.18) (n = 43)</td>
<td>0.97 (0.41–2.26) (n = 60)</td>
</tr>
<tr>
<td>p-tau181 per 1 SD increase</td>
<td>1.18 (0.86–1.61)</td>
<td>1.67 (0.88–3.18)</td>
<td>1.05 (0.74–1.47)</td>
</tr>
</tbody>
</table>

Abbreviations: APOE, apolipoprotein E; CI, confidence interval; GFAP, glial fibrillary acidic protein; NfL, neurofilament light chain; p-tau181, tau phosphorylated at threonine 181; SD, standard deviation; TC, total cholesterol.

*All logistic regression models were adjusted for age, sex, educational level, TC (exception: stratified analyses by TC), and APOE ε4 genotype (exception: stratified analyses by APOE ε4).


bParticipants not carrying APOE ε4 genotype (ε2/ε2, ε3/ε2, ε3/ε3).
all three biomarkers, especially NfL, with dementia risk was stronger among people with stroke. Altogether, the findings indicate that GFAP and, to a lesser extent, NfL are more promising than p-tau 181 for predicting dementia risk in the older White general population, and they suggest that high TC as risk factor for dementia might become evident only in synergism with other markers or pathologies. This observation would explain the inconsistent findings reported in the literature relating to associations of hypercholesterolemia and dementia.32–33

The results obtained in this cohort, which yielded GFAP as the strongest predictor for dementia diagnosis, shall be interpreted in relation to the nature of the ESTHER cohort, which mainly included dementia cases with both cerebrovascular and neurodegenerative injury. In the presence of brain injury astrocytes undergo structural, molecular, and functional changes and become “reactive.”34 Individuals with diffuse cerebrovascular injury might be more subject to widespread astrogliosis than patients with more localized neurodegenerative brain lesions, such as individuals with AD pathology alone, and this might accelerate cognitive decline because, among other things, reactive astrocytes might also lose their ability to regulate adult neurogenesis and to control circuits involved in learning and memory.35–36

Additionally, the strong predictive value of GFAP in this cohort supports a vascular link between brain and body health, possibly driven by neurovascular coupling,2 a multidimensional process involving several agents and signals, with astrocytes playing an instrumental role.37–38

In this cohort the association between biomarkers, especially GFAP and NfL, and risk of a dementia diagnosis seems to depend also on cholesterol levels. These findings could be observed both in the analyses with categorical and continuous values of biomarkers, and they remained stable after excluding outliers, which suggests that the observations relating to cholesterol patterns are particularly robust. Because high GFAP levels might also point to a possible dysregulation in brain cholesterol produced by astrocytes, these results might suggest a mechanism involving a cross-talk between central and peripheral cholesterol metabolism, possibly driven by the permeabilization of the
Another possible explaining factor could be the possible over-production of astrocyte-derived cholesterol driven by abnormal activation and proliferation of astrocytes, which in turn leads to increased AD-like pathology, as shown in lab mice, a hypothesis that could not be tested here because of the lack of valid Aβ measurements.

Regarding APOE ε4, dementia risk was higher in non-carriers with high GFAP and hypercholesterolemia than in carriers. These results are counterintuitive, but the statistically significant interaction term between GFAP and cholesterol in the group of non-carriers supports such observations. In a recent study, although GFAP was not associated with APOE ε4, significantly higher GFAP levels were observed only among APOE ε4 non-carriers with AD pathology and not among APOE ε4 carriers, and in a large population of older adults with mixed dementia pathologies hypercholesterolemia was linked to a lower dementia risk among APOE ε4 carriers. Furthermore, in the population-based Rotterdam cohort hypercholesterolemia was associated with lower Aβ levels in carriers but not in non-carriers. These results are in line with our findings obtained with GFAP, which point to lower odds for dementia among carriers than among non-carriers. The interaction term between TC and APOE ε4, although not statistically significant, possibly due to insufficient statistical power, also yielded increased odds for dementia, further pointing to a possible synergism between markers of neurodegeneration, especially GFAP and NFL, cholesterol, and APOE ε4 status in relation to dementia. However, it cannot be ruled out that the results are driven by the small number of participants in the APOE ε4 subgroups, hence they shall be interpreted with caution.

GFAP, NFL, and p-tau 181 were inserted in the models as continuous variables.

Blood p-tau181 has been shown to be a marker associated with progressive AD-related neurodegeneration and capable of distinguishing AD from vascular dementia and other neurodegenerative disorders in previous research. These results have been found in well-characterized cohorts with evidence of AD pathology in the brain. In our community-based cohort including both participants with AD and vascular dementia without neuropathological or biomarker evidence, p-tau181 was weakly associated with dementia and the results were not statistically significant. This might point to a strong contribution of cerebrovascular diseases to the clinical diagnoses of dementia in the ESTHER cohort and to the discrepancy between biological versus clinically defined AD. These findings would also support p-tau181 as a biomarker specifically increased in AD and not in other dementias. The presence of hypercholesterolemia had a marginal impact on the strength of the association, even if patterns comparable to those observed with the other biomarkers could be noticed, but the associations were not statistically significant. However, the low performance of p-tau181 in this cohort might also be explained with the platform used, because the performance of plasma phosphorylated tau may be platform dependent.
The findings of the present study also support the results of our previous study showing that hypercholesterolemia and cardiovascular disease changed the association of APOE ε4 with cognitive function in two independent cohorts\(^1\) and also seem to suggest that the use of a population-based cohort with high circulating peripheral cholesterol, as opposed to a well-characterized, but potentially selective cohort, might reveal different insights on the interaction between vascular and neurological diseases. However, to fully understand the relationship between markers of neurodegenerative disease and cholesterol it is important that future studies focus on the different components of TC, especially LDL cholesterol, which was not available for the whole cohort. Furthermore, in this study it was not possible to assess possible effects of cholesterol levels on biochemical reactions and the measurements of TC and blood biomarkers were performed at the same time point, which prevented a temporal exploration of the observed association and limited its interpretation. It would also be important to disentangle effects of APOE ε4, cholesterol, and vascular pathology, and investigate possible therapeutic opportunities, as suggested by a recent study that established a functional link among APOE ε4, cholesterol, myelination, and memory.\(^{36}\)

The findings of this cohort should also be replicated in populations of different racial and ethnical compositions,\(^{47}\) because the results of this study can only be generalized to the older White population. Other important limitations were the lack of brain biomarkers for AD pathology and of Aβ measurements in blood, and the dementia diagnoses made in community settings, which did not allow differentiation between AD and vascular dementia with certainty. Despite such limitations relating to the diagnoses made in a community setting it is to be noted that, if the ultimate goal of blood biomarkers of neurodegenerative diseases is to replace brain biomarkers, and if such biomarkers shall also be used in clinical settings, the use of a population-based cohort with mixed dementia pathologies and with diagnoses reflecting real-word clinical practice is of utmost importance to assess the predictive performance of the biomarkers with greater external validity. This study showed that the informative and diagnostic value of biomarkers developed in research cohorts with highly selected participants might be different in community-based cohorts and that the interplay with cerebrovascular injuries, and vascular and genetic risk factors shall also be considered when such biomarkers are used in community settings.

**ACKNOWLEDGMENTS**

The ESTHER study was funded by grants from the Saarland State Ministry for Social Affairs, Health, Women and Family Affairs (Saarbrücken, Germany); the Baden-Württemberg State Ministry of Science, Research and Arts (Stuttgart, Germany); the Federal Ministry of Education and Research (Berlin, Germany); and the Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany). UM is supported by the Marga and Walter Boll Foundation, Kerpen, Germany. None of the funding sources had a role in the conduct of the study, in the analysis or interpretation of the data, in the writing of this manuscript, or in the decision to submit it for publication.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Open access funding enabled and organized by Projekt DEAL.

**CONFLICTS OF INTEREST**

The authors report no conflicts of interest.

**Author disclosures** are available in the supporting information.

**REFERENCES**


**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.